Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Protalix BioTherapeutics (PLX) Tops Q1 EPS by 40c, Revenues Beat
June 1, 2020 6:53 AM EDTProtalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of $0.10, $0.40 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.65 million versus the consensus estimate of $6.6 million.
"The first quarter of 2020 has most certainly been transformational for Protalix, despite the COVID-19... More
